NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $85.94 +1.26 (+1.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$84.92▼$86.1450-Day Range$78.76▼$102.8752-Week Range$78.02▼$125.83Volume264,744 shsAverage Volume691,346 shsMarket Capitalization$20.43 billionP/E Ratio171.88Dividend YieldN/APrice Target$111.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside30.0% Upside$111.70 Price TargetShort InterestBearish1.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.00) to ($2.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector713th out of 936 stocksBiological Products, Except Diagnostic Industry121st out of 154 stocks 3.1 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has only been the subject of 4 research reports in the past 90 days.Read more about BioNTech's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.42% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in BioNTech has recently increased by 0.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 3.1 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for BioNTech this week, compared to 8 articles on an average week.Search Interest17 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat Follows12 people have added BioNTech to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from ($2.00) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 171.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 171.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesJuly 25 at 10:48 PM | marketwatch.comBioNTech SE ADR rises Thursday, outperforms marketJuly 25 at 5:43 PM | finance.yahoo.comMHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccineJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 24 at 12:11 PM | reuters.comUK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variantJuly 22, 2024 | marketwatch.comBioNTech SE ADR rises Monday, still underperforms marketJuly 22, 2024 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on BioNTech SE (BNTX)July 22, 2024 | globenewswire.comBioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024July 22, 2024 | globenewswire.comBioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 20, 2024 | ca.finance.yahoo.comBNTX Sep 2024 100.000 putJuly 20, 2024 | ca.finance.yahoo.comBNTX Dec 2025 120.000 putJuly 20, 2024 | ca.finance.yahoo.comBNTX Jun 2025 105.000 putJuly 2, 2024 | investorplace.com3 Nasdaq Stocks to Sell in July Before They Crash & BurnJune 27, 2024 | globenewswire.comPfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European UnionJune 24, 2024 | globenewswire.comBioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate CancerJune 17, 2024 | benzinga.comWhy Is Pfizer Partner BioNTech Stock Trading Lower On Monday?June 17, 2024 | reuters.comUS FDA puts partial clinical hold on BioNTech's early-stage study of cancer drugJune 13, 2024 | seekingalpha.comBioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm SkepticalSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$111.70 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+29.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio172.14 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins4.01% Pretax Margin5.55% Return on Equity0.55% Return on Assets0.49% Debt Debt-to-Equity Ratio0.01 Current Ratio11.38 Quick Ratio11.16 Sales & Book Value Annual Sales$4.13 billion Price / Sales4.95 Cash Flow$5.25 per share Price / Cash Flow16.40 Book Value$92.17 per share Price / Book0.93Miscellaneous Outstanding Shares237,730,000Free Float192,083,000Market Cap$20.46 billion OptionableOptionable Beta0.23 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $823.67kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $846.46kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $817.16kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $612.05kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsModernaNASDAQ:MRNABiogenNASDAQ:BIIBargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHView All CompetitorsInstitutional OwnershipBaillie Gifford & Co.Sold 82,641 shares on 7/25/2024Ownership: 3.481%Slow Capital Inc.Bought 5,467 shares on 7/24/2024Ownership: 0.021%Fifth Third BancorpSold 412 shares on 7/22/2024Ownership: 0.007%China Universal Asset Management Co. Ltd.Sold 7,101 shares on 7/20/2024Ownership: 0.005%LA Financiere DE L EchiquierBought 20,427 shares on 7/18/2024Ownership: 0.099%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The company is currently developing FixVac product candidates, such as BNT111 and BNT112, which are in various stages of clinical trials. Recent developments show promising results in the company's pipeline, indicating potential future growth. BioNTech SE has a strong focus on innovation and research, positioning itself as a leader in the biotechnology industry. The current stock price of BioNTech SE reflects positive investor sentiment and growth potential. Cons Investors should be bearish about investing in BioNTech SE for these reasons: Biotechnology investments can be volatile and subject to regulatory approvals, which may impact the company's financial performance. Competition in the biotechnology sector is intense, with other companies also developing immunotherapies for similar indications. Market uncertainties and global economic conditions can affect the demand for BioNTech SE's products and services. Investing in biotechnology companies carries inherent risks related to clinical trial outcomes and product commercialization. Fluctuations in the stock price of BioNTech SE may be influenced by external factors beyond the company's control. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 1, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX stock has decreased by 18.6% and is now trading at $85.94. View the best growth stocks for 2024 here. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Monday, May, 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.60. The company earned $203.69 million during the quarter, compared to analysts' expectations of $589.96 million. BioNTech had a net margin of 4.01% and a trailing twelve-month return on equity of 0.55%. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. Does BioNTech have any subsidiaries? BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others. When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's top institutional investors include Baillie Gifford & Co. (3.48%), LA Financiere DE L Echiquier (0.10%), Baader Bank Aktiengesellschaft (0.06%) and IMC Chicago LLC. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:BNTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.